Radiopharm Theranostics Limited American Depositary Shares
RADX
Radiopharm Theranostics Ltd is a clinical-stage radiotherapeutics company focused on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. It develops and commercializes radiopharmaceutical platforms for therapeutic and diagnostic applications in precision oncology. The Company develops targeted and scientifically validated radiopharmaceutical technologies in pre-clinical and clinical stages. It has one reportable segment, being the research, development, and commercialization of health technologies. The Company operates in Australia and the United States, with maximum revenue from the United States.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$0.653 – $0.757
Volume29,944
Market cap$12M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for RADX.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for RADX.
Recent news
Company coverage with links to the original publishers.
Radiopharm Theranostics received FDA alignment on a pivotal Phase 3 trial design for RAD101, a novel imaging agent for detecting brain metastases. The single multicenter trial will enroll approximately 280 patients and is substantially smaller than historical imaging studies, reflecting significant unmet medical need. The company expects to initiate the trial in the first half of 2027 with manufacturing support from Siemens Healthineers.
Radiopharm Theranostics announced successful completion of an End-of-Phase 2 meeting with the FDA for RAD101, a brain metastases imaging agent that demonstrated 93% concordance with MRI. The company is preparing to initiate a pivotal Phase 3 trial in 1Q27 and has secured a manufacturing partnership with Siemens Healthineers. Additionally, Radiopharm reported positive Phase 1 imaging data for RAD301 in pancreatic cancer and advanced RAD202 to the fourth dosing cohort in its HER2+ solid tumor study.
Radiopharm Theranostics announced dosing of the first patient in the second cohort of its Phase 1/2a clinical trial of RV-01 (177Lu-Betabart) at 70 mCi, following a positive recommendation from the Safety and Monitoring Committee. RV-01 is a 177Lutetium-tagged monoclonal antibody targeting B7-H3 in patients with B7-H3 expressing solid tumors, developed through a joint venture with MD Anderson Cancer Center.
Radiopharm Theranostics completed enrollment in its Phase 2b trial for RAD 101, an imaging agent for brain metastases, with interim data showing 90% concordance with MRI. The company also presented Phase 0/1 data for RAD 202 showing favorable safety and tumor uptake, received DSMC approval to advance to the next dose level, and initiated two new First-In-Human trials for radiotherapeutic assets RV-01 and RAD 402. Cash position declined to $19.2 million from $34.5 million in the prior quarter.
Radiopharm Theranostics received a positive recommendation from its Data Safety and Monitoring Committee to escalate its Phase 1 'HEAT' clinical trial of RAD202 to the next dose level of 130mCi in HER2-positive advanced solid tumor patients. The company remains on track to complete Phase 1 dose escalation by end of 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.